29 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
-clinical package
2H 2024
Initiate Phase 2 clinical trial
1H 2025
Financial Results Highlights
Kiora ended the first quarter of 2024 with $31.3
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
to any of the foregoing and all proposed labels, labelling, package inserts, monographs and packaging for a Licensed Product in a particular country
8-K
EX-99.1
7gduuj1 57xi
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
8-K
34ipgl
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
8-K
EX-99.1
d04 ub3cyx8fm8t
2 Dec 19
EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study
6:55am
8-K
EX-99.1
bubxqxl8mx2f3w
22 Nov 19
Other Events
6:55am
8-K
EX-10.1
j61cdobjfa74qa pc2kq
10 Jul 15
EyeGate Signs Licensing Agreement with Valeant Pharmaceuticals for EGP-437 Combination Product in Uveitis
12:00am
10-K
qxfw x3o810
31 Mar 15
Annual report
12:00am
424B4
d2o2h2ro4ob
13 Feb 15
Prospectus supplement with pricing info
12:00am
FWP
ftt9lj6gftza
16 Jan 15
Free writing prospectus
12:00am